|
|
|
|
|
Legal status
Patent not validated
| (51) | INT.CL. | A61K 38/06 | |
| A61K 45/06 | |||
| A61K 31/4178 | |||
| A61P 31/12 |
| (11) | Number of the document | 2488192 |
| (13) | Kind of document | T |
| (96) | European patent application number | 10765917.9 |
| Date of filing the European patent application | 2010-10-08 | |
| (97) | Date of publication of the European application | 2012-08-22 |
| (45) | Date of publication and mention of the grant of the patent | 2017-08-30 |
| (46) | Date of publication of the claims translation |
| (86) | Number | PCT/US2010/051898 |
| Date | 2010-10-08 |
| (87) | Number | WO 2011/046811 |
| Date | 2011-04-21 |
| (30) | Number | Date | Country code |
| 250648 P | 2009-10-12 | US | |
| 899840 | 2010-10-07 | US |
| (72) |
LEMM, Julie A., US
VOSS, Stacey A., US
GAO, Min, US
CHANIEWSKI, Susan E., US
SHEAFFER, Amy K., US
MCPHEE, Fiona, US
|
| (73) |
Bristol-Myers Squibb Holdings Ireland,
Hinterbergstrasse 16, 6312 Steinhausen,
CH
|
| (54) | COMBINATIONS OF A SPECIFIC HCV NS5A INHIBITOR AND AN HCV NS3 PROTEASE INHIBITOR |
| COMBINATIONS OF A SPECIFIC HCV NS5A INHIBITOR AND AN HCV NS3 PROTEASE INHIBITOR |